Pictet Asset Management Holding SA lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 17.3% in the third quarter, HoldingsChannel.com reports. The firm owned 887,598 shares of the medical research company’s stock after selling 186,072 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Thermo Fisher Scientific were worth $599,270,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in TMO. BlackRock Inc. bought a new stake in Thermo Fisher Scientific in the second quarter worth approximately $15,501,867,000. Corient Private Wealth LP bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at $382,547,000. Bank of New York Mellon Corp bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $1,974,561,000. Bank of America Corp DE bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $1,952,930,000. Finally, Legal & General Group Plc purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $1,122,351,000. 89.23% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
TMO has been the topic of a number of recent research reports. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating and upped their target price for the company from $660.00 to $690.00 in a report on Tuesday, September 1st. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. TD Cowen raised their target price on Thermo Fisher Scientific from $760.00 to $810.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Finally, CLSA assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $683.64.
View Our Latest Report on Thermo Fisher Scientific
Key Stories Impacting Thermo Fisher Scientific
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: The board authorized up to $5 billion in share repurchases, replacing the prior authorization, which had $1 billion remaining. The program has no expiration date and could support per-share results and signal confidence in the business. Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
- Positive Sentiment: Recent quarterly results were better than expected: EPS of $6.68 beat the $6.40 consensus, while revenue of $12.14 billion exceeded estimates and increased 9.1% year over year. Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings
- Positive Sentiment: Thermo Fisher declared a quarterly dividend of $0.47 per share, payable January 15, 2027. The annualized dividend is $1.88 per share, though the indicated yield is modest at about 0.3%. Thermo Fisher Scientific Announces Quarterly Dividend
- Positive Sentiment: The company introduced value-priced AmpSure qPCR master mixes, adding an offering aimed at labs seeking dependable testing performance at lower cost. Thermo Fisher Introduces AmpSure Universal qPCR Master Mixes
- Neutral Sentiment: Market research reports point to growth in oligonucleotide synthesis, mRNA manufacturing, protein labeling and Q-TOF mass spectrometry—areas related to Thermo Fisher’s markets. These industry forecasts suggest potential demand tailwinds, but do not provide company-specific sales or earnings guidance. Global Oligonucleotide Synthesis Services Market Report 2026
Insider Transactions at Thermo Fisher Scientific
In other news, CEO Marc Casper sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. The trade was a 7.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 50,046 shares of company stock worth $30,779,192. Company insiders own 0.33% of the company’s stock.
Thermo Fisher Scientific Trading Up 2.7%
Shares of TMO opened at $694.93 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $712.17. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market capitalization of $257.48 billion, a P/E ratio of 36.65, a P/E/G ratio of 2.83 and a beta of 0.84. The firm’s 50 day simple moving average is $661.03 and its 200 day simple moving average is $554.78.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. The business had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.79 earnings per share. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.92%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research.
The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
Featured Stories
- Five stocks we like better than Thermo Fisher Scientific
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
